Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supple… Read more
Integrated Biopharma Inc (INBP) - Total Liabilities
Latest total liabilities as of September 2025: $5.05 Million USD
Based on the latest financial reports, Integrated Biopharma Inc (INBP) has total liabilities worth $5.05 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Integrated Biopharma Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Integrated Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Integrated Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Integrated Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metalex Ventures Ltd
PINK:MXTLF
|
USA | $2.65 Million |
|
Swiftmerge Acquisition Corp. Warrants
NASDAQ:IVCPW
|
USA | $17.85 Million |
|
AVI Global Trust PLC
LSE:AGT
|
UK | £168.76 Million |
|
APPLIED MATERIALS (AP2.SG)
STU:AP2
|
Germany | €14.81 Billion |
|
North Stawell Minerals Ltd
AU:NSM
|
Australia | AU$251.92K |
|
Infracommerce CXaaS S.A
SA:IFCM3
|
Brazil | R$998.52 Million |
|
STRYKER - Dusseldorf Stock Exchang
DU:SYK
|
Germany | €23.68 Billion |
|
Fertoz Ltd
AU:FTZ
|
Australia | AU$2.55 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Integrated Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Integrated Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Integrated Biopharma Inc (2000–2025)
The table below shows the annual total liabilities of Integrated Biopharma Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $4.58 Million | -34.22% |
| 2024-06-30 | $6.97 Million | +6.07% |
| 2023-06-30 | $6.57 Million | -1.57% |
| 2022-06-30 | $6.67 Million | -39.90% |
| 2021-06-30 | $11.11 Million | -34.19% |
| 2020-06-30 | $16.88 Million | -5.70% |
| 2019-06-30 | $17.90 Million | -9.63% |
| 2018-06-30 | $19.80 Million | -6.25% |
| 2017-06-30 | $21.12 Million | -5.74% |
| 2016-06-30 | $22.41 Million | +7.03% |
| 2015-06-30 | $20.94 Million | -3.68% |
| 2014-06-30 | $21.74 Million | -5.08% |
| 2013-06-30 | $22.90 Million | +2.88% |
| 2012-06-30 | $22.26 Million | +4.29% |
| 2011-06-30 | $21.34 Million | +9.22% |
| 2010-06-30 | $19.54 Million | +3.25% |
| 2009-06-30 | $18.93 Million | -7.64% |
| 2008-06-30 | $20.49 Million | -15.36% |
| 2007-06-30 | $24.21 Million | +103.94% |
| 2006-06-30 | $11.87 Million | +15.58% |
| 2005-06-30 | $10.27 Million | +38.51% |
| 2004-06-30 | $7.42 Million | +188.34% |
| 2003-06-30 | $2.57 Million | +6.19% |
| 2002-06-30 | $2.42 Million | -33.57% |
| 2001-06-30 | $3.65 Million | +65.20% |
| 2000-06-30 | $2.21 Million | -- |